Eugen Kubala
About
In The Last Decade
Eugen Kubala
18 papers receiving 87 citations
Peers
Comparison fields: 5 of 36
- Oncology 49
- Epidemiology 29
- Molecular Biology 24
- Surgery 18
- Infectious Diseases 17
Countries citing papers authored by Eugen Kubala
This map shows the geographic impact of Eugen Kubala's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Eugen Kubala with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Eugen Kubala more than expected).
Fields of papers citing papers by Eugen Kubala
This network shows the impact of papers produced by Eugen Kubala. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Eugen Kubala. The network helps show where Eugen Kubala may publish in the future.
Co-authorship network of co-authors of Eugen Kubala
This figure shows the co-authorship network connecting the top 25 collaborators of Eugen Kubala. A scholar is included among the top collaborators of Eugen Kubala based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Eugen Kubala. Eugen Kubala is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
| # | Work | Indexed citations |
|---|---|---|
| 1 | 2 | |
| 2 | 1 | |
| 3 | 2 | |
| 4 | 6 | |
| 5 | 4 | |
| 6 | Long-term Survival with Ipilimumab: Experience from a National Expanded Access Program for Patients with Melanoma. | 20 |
| 7 | 4 | |
| 8 | [High-dose interferon alpha in treatment of patients with malignant melanoma, monitoring of predictive and prognostic biomarkers]. | 1 |
| 9 | [Chemotherapy and biological treatment in the complex management of large intestinal and rectal carcinomas. When, why, how?]. | 1 |
| 10 | 19 | |
| 11 | [Resection of metastatic nondifferentiated carcinoma of sternum with thoracic wall reconstruction and simultaneous myocardial revascularization for ischemic heart disease--case report]. | 1 |
| 12 | 6 | |
| 13 | Agreement and disagreement between laboratories in species identification of mycobacteria. | 1 |
| 14 | 18 | |
| 15 | [Antitubercular agents. XI. Function derivatives of 5-substituted 2-pyrazinecarboxylic acid]. | 1 |
| 16 | Some aspects of diseases caused by atypical mycobacteria. | 4 |
| 17 | [Antitubercular agents. X. The action of derivatives of 3-substituted 2 pyrazinecarboxylic acid]. | 1 |
| 18 | [Comparison of the various preparation methods for culturing Mycobacterium tuberculosis from specimens and the simultaneously performed guinea pig test]. | 0 |
| 19 | 1 |
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.